Miglustat / OGT 918 in the Treatment of Cystic Fibrosis

Summary

Cystic fibrosis is a genetic disease caused by mutation of the cystic fibrosis transmembrane conductance regulator (CFTR). The purpose of the study is to investigate the effects of miglustat on CFTR function in cystic fibrosis patients.

Timeline

Start

2007-11

Primary completion

2008-02

Completion

2008-03

Outcome

Outcome not reported

Stopped: “Methodology applied did not meet all criteria required per guidelines”

Drugs

Indications